keyword
MENU ▼
Read by QxMD icon Read
search

Plaque psoriasis

keyword
https://www.readbyqxmd.com/read/28432647/the-gender-attention-observational-study-gender-and-hormonal-status-differences-in-the-incidence-of-adverse-events-during-cyclosporine-treatment-in-psoriatic-patients
#1
Delia Colombo, Giuseppe Banfi, Nicoletta Cassano, Alessandra Graziottin, Gino Antonio Vena, Giovanni Gualberto Fiori, Emanuela Zagni, Luca Stingeni, Sergio Chimenti, Enzo Berardesca, Giuseppe Micali, Giuseppe Albertini, Clara De Simone, Gilberto Bellia
INTRODUCTION: Female sex has been shown to be a risk factor for the development of adverse drug reactions; however, this has not been studied for cyclosporine (CsA). The aim of this study was to investigate, in Italian dermatological practice, the influence of gender and menopause and related hormones on the incidence of adverse events (AEs) during CsA treatment in psoriatic patients. METHODS: Multicenter, prospective, observational study conducted from May 2011 to June 2013...
April 21, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28423301/risankizumab-versus-ustekinumab-for-moderate-to-severe-plaque-psoriasis
#2
Kim A Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James Krueger, Jean-Philippe Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen Tyring, Beate R Berner, Sudha Visvanathan, Chandrasena Pamulapati, Nathan Bennett, Mary Flack, Paul Scholl, Steven J Padula
Background Interleukin-23 is thought to be critical to the pathogenesis of psoriasis. We compared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit and thus prevents interleukin-23 signaling, and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, in patients with moderate-to-severe plaque psoriasis. Methods We randomly assigned a total of 166 patients to receive subcutaneous injections of risankizumab (a single 18-mg dose at week 0 or 90-mg or 180-mg doses at weeks 0, 4, and 16) or ustekinumab (45 or 90 mg, according to body weight, at weeks 0, 4, and 16)...
April 20, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28418602/expression-of-low-density-lipoprotein-related-receptors-5-and-6-lrp5-6-in-psoriasis-skin
#3
Albert Duvetorp, Renate Slind Olsen, Helena Nyström, Marita Skarstedt, Olaf Dienus, Ulrich Mrowietz, Jan Söderman, Oliver Seifert
Low-density lipoprotein-related receptors 5 and 6 (LRP5/6) are transmembrane receptors with key functions in canonical Wnt signaling. Wnt ligands are thought to play an important role in innate immunity and psoriasis and recent studies assigned LRP5/6 anti-inflammatory properties. The objective of this study was to investigate the expression of LRP5 and LRP6 in lesional and non-lesional skin in peripheral blood and in mononuclear cells of patients with chronic plaque type psoriasis compared with control individuals...
April 18, 2017: Experimental Dermatology
https://www.readbyqxmd.com/read/28416342/long-term-safety-and-tolerability-of-apremilast-in-patients-with-psoriasis-pooled-safety-analysis-for-%C3%A2-156%C3%A2-weeks-from-2-phase-3-randomized-controlled-trials-esteem-1-and-2
#4
Jeffrey Crowley, Diamant Thaçi, Pascal Joly, Ketty Peris, Kim A Papp, Joana Goncalves, Robert M Day, Rongdean Chen, Kamal Shah, Carlos Ferrándiz, Jennifer C Cather
BACKGROUND: Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis. OBJECTIVE: Assess long-term safety of oral apremilast in psoriasis patients. METHODS: Safety findings are reported for 0 to ≥156 weeks from the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2. RESULTS: The 0 to ≥156-week apremilast-exposure period included 1184 patients treated twice daily with apremilast 30 mg (1902...
April 14, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28407625/comparison-of-occlusive-and-open-application-in-a-psoriasis-plaque-test-design-examplarily-using-investigations-of-mapracorat-0-1-ointment-versus-vehicle-and-reference-drugs
#5
Walter Wigger-Alberti, Ragna Williams, Yi-Ling von Mackensen, Maciej Hoffman-Wecker, Ulrike Grossmann, Gerald Staedtler, Richard Nkulikiyinka, Kaweh Shakery
BACKGROUND/AIMS: Psoriasis plaque tests (PPTs) are important tools in the early phases of antipsoriatic drug development. Two distinct PPT design variants (open vs. occluded drug application) are commonly used, but no previous work has aimed to directly compare and contrast their performance. METHODS: We compared the antipsoriatic efficacy of mapracorat 0.1% ointment and reference drugs reported in 2 separate studies, representing open and occluded PPT designs. The drug effect size was measured by sonography (mean change in echo-poor band thickness), chromametry, and standardized clinical assessment...
April 14, 2017: Skin Pharmacology and Physiology
https://www.readbyqxmd.com/read/28406130/is-the-periodontal-status-a-risk-factor-for-the-development-of-psoriasis
#6
G Sarac, Y Kapicioglu, S Cayli, A Altas, S Yologlu
BACKGROUND AND OBJECTIVES: Psoriasis is a common, chronic, inflammatory, and hyperproliperative skin disease. It has been known that the infectious agents play a role in triggering and exacerbation of the disease. Periodontal diseases are chronic inflammatory gum diseases initiated by microorganisms in dental plaques. This study intended to determine the role of periodontal diseases, as chronic infective foci in psoriasis. MATERIALS AND METHODS: A total of 76 patients, who applied to Faculty of Medicine, Department of Dermatology, İnönü University, diagnosed as psoriasis and a control group consisting of 76 dermatologic patients without any systemic disease at similar age and gender were included the study...
April 2017: Nigerian Journal of Clinical Practice
https://www.readbyqxmd.com/read/28400641/secukinumab-first-in-class-interleukin-17a-inhibitor-for-the-treatment-of-psoriasis
#7
Kiran Godse
Psoriasis is a complex inflammatory disease that occurs in genetically susceptible individuals and presents with the development of erythematous scaly plaques on the skin. Interleukins (ILs) in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus become targets for recent biologic drug development. Secukinumab is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. Secukinumab recently approved for use as first-line systemic therapy in a patient with moderate to severe psoriasis has been studied first in psoriasis before other diseases...
March 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28400341/efficacy-and-safety-of-total-glucosides-of-paeony-combined-with-acitretin-in-the-treatment-of-moderate-to-severe-plaque-psoriasis-a-double-blind-randomised-placebo-controlled-trial
#8
Chen Yu, Xueli Fan, Zhenlu Li, Xiaoming Liu, Gang Wang
Although acitretin has been widely used for the treatment of psoriasis, additional safer and more effective approaches, including traditional Chinese medicine, are needed. To investigate the efficacy and safety of total glucosides of paeony (TGP) combined with acitretin in the treatment of moderate-to-severe plaque psoriasis. A randomised, double-blind, placebo-controlled, multi-centre clinical study was conducted. In total, 108 patients with moderate-to-severe plaque psoriasis were randomly assigned to treatment with "TGP plus acitretin" (group A) or "placebo plus acitretin" (group B) for 12 weeks...
April 1, 2017: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/28398415/misdiagnosed-crusted-scabies-in-an-aids-patient-leads-to-hyperinfestation
#9
Niloofar Yari, C Helen Malone, Antonio Rivas
Crusted scabies is a severe, highly contagious form of classic scabies caused by the mite Sarcoptes scabiei var hominis. Crusted scabies is more common in immunosuppressed populations and overcrowded environments. In this condition, the host's immune system is overwhelmed and unable to defend against the mites on the skin, resulting in hyperinfestation of the host. Diagnosis can be challenging because the condition resembles other common skin conditions, such as plaque psoriasis. Furthermore, delayed diagnosis and inappropriate treatment can lead to worsening of the condition...
March 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28397079/secukinumab-is-efficacious-and-safe-in-hispanic-patients-with-moderate-to-severe-plaque-psoriasis-pooled-analysis-of-four-phase-3-trials
#10
Sandra Adsit, Enrique Rivas Zaldivar, Howard Sofen, Ignacio Dei-Cas, César Maldonado García, Elkin O Peñaranda, Luís Puig, Xiangyi Meng, Todd Fox, Adriana Guana
INTRODUCTION: There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was to compare the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients. METHODS: Data were pooled from four phase 3 studies of secukinumab in patients with moderate-to-severe plaque psoriasis. Patients who self-identified as Hispanic were included in the Hispanic subgroup...
April 10, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28396102/efficacy-of-tofacitinib-for-the-treatment-of-nail-psoriasis-two-52-week-randomized-controlled-phase-3-studies-in-patients-with-moderate-to-severe-plaque-psoriasis
#11
Joseph F Merola, Boni Elewski, Svitlana Tatulych, Shuping Lan, Anna Tallman, Mandeep Kaur
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor. Efficacy and safety of tofacitinib in patients with moderate-to-severe plaque psoriasis have been demonstrated. OBJECTIVE: We sought to assess the efficacy of tofacitinib for the treatment of nail psoriasis over a period of 52 weeks. METHODS: In 2 identical phase 3 studies (OPT Pivotal 1 and 2), patients were randomized 2:2:1 to receive tofacitinib 5 mg, tofacitinib 10 mg, or placebo, twice daily...
April 7, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28391657/apremilast-an-oral-phosphodiesterase-4-inhibitor-in-the-treatment-of-japanese-patients-with-moderate-to-severe-plaque-psoriasis-efficacy-safety-and-tolerability-results-from-a-phase-2b-randomized-controlled-trial
#12
Mamitaro Ohtsuki, Yukari Okubo, Mayumi Komine, Shinichi Imafuku, Robert M Day, Peng Chen, Rosemary Petric, Allan Maroli, Osamu Nemoto
Apremilast, an oral, small-molecule phosphodiesterase 4 inhibitor, works intracellularly within immune cells to regulate inflammatory mediators. This phase 2b randomized, placebo-controlled study evaluated efficacy and safety of apremilast among Japanese patients with moderate to severe plaque psoriasis. In total, 254 patients were randomized to placebo, apremilast 20 mg b.i.d. (apremilast 20) or apremilast 30 mg b.i.d. (apremilast 30) through week 16; thereafter, all placebo patients were re-randomized to apremilast 20 or 30 through week 68...
April 9, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28390479/the-immunology-of-atopic-dermatitis-and-its-reversibility-with-broad-spectrum-and-targeted-therapies
#13
REVIEW
Patrick M Brunner, Emma Guttman-Yassky, Donald Y M Leung
Atopic dermatitis (AD), the most common chronic inflammatory skin disease, is driven by both terminal keratinocyte differentiation defects and strong type 2 immune responses. In contrast to chronic plaque-type psoriasis, AD is now understood to be a much more heterogeneous disease, with additional activation of TH22, TH17/IL-23, and TH1 cytokine pathways depending on the subtype of the disease. In this review we discuss our current understanding of the AD immune map in both patients with early-onset and those with chronic disease...
April 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28387421/apn-cd13-is-over-expressed-by-psoriatic-fibroblasts-and-is-modulated-by-cgrp-and-il-4-but-not-by-retinoic-acid-treatment
#14
Pascale Gerbaud, Jean Guibourdenche, Rafika Jarray, Marc Conti, Patricia Palmic, Stéphanie Leclerc-Mercier, Julie Bruneau, Olivier Hermine, Yves Lepelletier, Françoise Raynaud
Psoriasis vulgaris is a common skin inflammatory disease characterized by recurrent flare episodes associated with scaly well-demarcated skin plaques. Skin biopsies from psoriatic patients with high PASI score (22.67 ± 8.67) and from HD were used to study APN/CD13. APN/CD13 is over-expressed in LP and nLP compare to HD skins and fibroblasts. This over-expression is positively correlated with specific enzymatic activity enhancement. However, discrepancies between APN/CD13 expression in LP and nLP prompt us to focus our study on APN/CD13 modulation...
April 7, 2017: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/28386142/nail-psoriasis-what-a-rheumatologist-should-know-about
#15
REVIEW
Barbara Nieradko-Iwanicka
Psoriasis is a chronic recurrent inflammatory skin disease with prevalence of 1-3%. Nail psoriasis affects 10-90% of patients with plaque psoriasis. The aim of the article is to review the literature for the correlation between nail psoriasis and psoriatic arthritis (PsA) to provide rheumatologists a short review on features of nail psoriasis, methods of their assessment and possible clinical repercussions. The PubMed database was searched using the key words 'nail psoriasis' and 'psoriatic arthritis'. Psoriasis involving the nail matrix shows up as changes such as pitting, Beau lines, leukonychia, red spots in the lunula, or nail plate crumbling...
2017: Reumatologia
https://www.readbyqxmd.com/read/28384966/metabolic-syndrome-in-psoriasis-among-urban-south-indians-a-case-control-study-using-sam-ncep-criteria
#16
Banavasi S Girisha, Neetha Thomas
INTRODUCTION: Psoriasis is a chronic inflammatory disease of the skin associated with increased cardiovascular morbidity. Metabolic syndrome is a significant forecaster of cardiovascular events. AIM: To assess the association of metabolic syndrome and its components in patients with psoriasis and to compare it with the age and sex matched control group. MATERIALS AND METHODS: We conducted a hospital based case-control study on 156 adult patients with chronic plaque psoriasis and 156 patients with skin diseases other than psoriasis...
February 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28380251/apremilast-and-suicidality-a-retrospective-analysis-of-three-large-databases-the-faers-eudravigilance-and-a-large-single-center-u-s-patient-population
#17
P P Vakharia, K A Orrell, D Lee, S M Rangel, E Lund, A E Laumann, B Nardone
Apremilast is a small molecule phosphodiesterase-4 inhibitor approved by the United States Food and Drug Administration (FDA) in 2014 for the treatment of adult patients with moderate-to-severe plaque psoriasis and for psoriatic arthritis.(1) Worsening depression, suicide attempts, suicidal ideation, and suicidal behavior have previously been reported in clinical trials and post-marketing surveillance data, and details are included in the Full Prescribing Information.(1) Moreover, a post-marketing statement recently issued now indicates that completed suicide has also been reported...
April 5, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28374122/the-role-of-pharmacogenetics-in-chronic-plaque-psoriasis-update-of-the-literature
#18
REVIEW
Marina Talamonti, Simone D'Adamio, Luca Bianchi, Marco Galluzzo
Psoriasis is a chronic inflammatory disease triggered by both genetic and environmental factors. Systemic and biologic therapies used to treat moderate-to-severe psoriasis show significant variability in efficacy, are associated with various degrees of toxicity, and, for biologic therapies, are expensive. There is a great need for non-invasive biomarkers to predict treatment outcomes of these therapies and to individualize care for patients with psoriasis. This article reviews currently recognized pharmacogenetic targets related to the treatment of chronic plaque psoriasis, in particular to biologic therapies...
April 3, 2017: Molecular Diagnosis & Therapy
https://www.readbyqxmd.com/read/28370467/the-effect-of-body-weight-on-the-efficacy-and-safety-of-ixekizumab-results-from-an-integrated-database-of-3-randomized-controlled-phase-3-studies-of-patients-with-moderate-to-severe-plaque-psoriasis
#19
K Reich, L Puig, L Mallbris, L Zhang, O Osuntokun, C Leonardi
BACKGROUND: There is concern that increased body weight may impact efficacy of some therapies used to treat psoriasis. OBJECTIVE: To evaluate the effect of body weight on response to ixekizumab treatment in moderate-to-severe psoriasis patients. METHODS: Patients were characterized under 3 body weight categories (<80 kg, 80 to 100 kg, ≥100 kg) in this preplanned subgroup analysis from an integrated database of 3 multicenter, randomized, double-blind, controlled Phase 3 clinical studies (UNCOVER -1, UNCOVER-2, and UNCOVER-3)...
April 1, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28352929/effectiveness-of-adalimumab-in-the-treatment-of-scalp-and-nail-affection-in-patients-with-moderate-to-severe-plaque-psoriasis-in-routine-clinical-practice
#20
Kuzma Khobzey, Iryna Liskova, Andrea Szegedi, Lev Pavlovsky, Tomaž Lunder, Külli Kingo, Jovan Miljković, Juraj Péč, Maša Bohinc, Maja Hojnik
INTRODUCTION: Data on the effectiveness of biologics in the treatment of nail and scalp psoriasis (PSO) in a routine clinical setting are scarce. The aim of this study was therefore to evaluate the effectiveness of adalimumab in the treatment of nail and scalp psoriatic lesions in routine dermatologic practice. METHODS: Five hundred one patients were analyzed in this observational study; 157 patients had nail involvement (nail PSO set; NPS) and 404 had scalp involvement (scalp PSO set; SPS)...
March 2017: Acta Dermatovenerologica Alpina, Panonica, et Adriatica
keyword
keyword
82378
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"